Dysbiosis of the human skin mycobiome in patients receiving systemic IL-23 inhibitors
Background: Systemic inhibition of pro-inflammatory cytokines affects the skin microbiome; however, the impact of systemic anti-inflammatory therapy on the skin fungal microbiome is poorly understood. To examine the effects of cytokine inhibition on the fungal community on human skin and oral mucosa...
Saved in:
Main Authors: | Yuta Koike, Sayaka Kuwatsuka, Daisuke Motooka, Hiroyuki Murota |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893024000807 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential
by: Ines Hadrich, et al.
Published: (2025-01-01) -
Mycobiome analyses of critically ill COVID-19 patients
by: Danielle Weaver, et al.
Published: (2025-02-01) -
Assessment of The Impact of Apremilast on Levels of IL-17, IL-23, and Lipids in Obese Psoriatic Patient
by: Haitham M. Saad, et al.
Published: (2024-12-01) -
The mycobiome in human cancer: analytical challenges, molecular mechanisms, and therapeutic implications
by: Ting Ding, et al.
Published: (2025-01-01) -
Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern EuropeansResearch in context
by: Ben Krause-Kyora, et al.
Published: (2025-03-01)